Introduction

Pembrolizumab has provided sustained anti-tumor activity with all complete responses maintained after approximately 4 years of follow-up. Autologous CAR-T cells are highly effective, yet not always feasible in children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. New research in a mouse model provides new insights into maternal and fetal iron homeostasis. And finally, ironing out beta thalassemia during pregnancy.